In a double-blind, placebo-controlled study, treatment with a human mAb to TSLP resolved airway inflammation and attenuated allergen-induced bronchoconstriction, findings consistent with TSLP as a therapeutic target in patients with allergic asthma.130. This evidence concerns the gene TSLP and allergic asthma.